The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...
Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform ...
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...
A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in ...
Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated IDA management, this series of Ace the Case sessions will highlight key teaching points ...
A clinical trial led by Dr. Keith McCrae of Cleveland Clinic has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback